Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07276776 for Type 2 Diabetes Mellitus is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes 40
Clinical Trial NCT07276776 is an interventional study for Type 2 Diabetes Mellitus that is active, not recruiting. It started on 12 December 2025 with plans to enroll 40 participants. Led by Insulet Corporation, it is expected to complete by 30 March 2026. The latest data from ClinicalTrials.gov was last updated on 31 March 2026.
Brief Summary
This is a single arm feasibility study to evaluate the Omnipod M System in adults with Type 2 Diabetes with the aim to enroll to 40 participants aged 18-75 years with type 2 diabetes to have a minimum of 20 participants initiate the use of Omnipod M System and the goal of 16 participants completing the 6-week treatment period.
Official Title
An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes
Conditions
Type 2 Diabetes MellitusOther Study IDs
- Evolution 3
NCT ID Number
Start Date (Actual)
2025-12-12
Last Update Posted
2026-03-31
Completion Date (Estimated)
2026-03-30
Enrollment (Estimated)
40
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Type 2 Diabetes
T2D
Omnipod 5
Automated Insulin Delivery System
T2D
Omnipod 5
Automated Insulin Delivery System
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalExperimental- Participants with Type 2 diabetes | Omnipod M system The Omnipod M system will allow user to use a lower glucose target and improve systems glucose control |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Percent of time in hypoglycemic range <70mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Percent of time in hyperglycemic range >180 mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Mean Glucose | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Percentage of time <54 mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Percentage of time >250mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Percentage of time >300mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Percent of time between 70-180mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Standard Deviation | Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the standard deviation (SD) | Comparing baseline metrics to the end of the treatment period (Day45) |
Coefficient of Variation | Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the coefficient of variation (CV) | Comparing baseline metrics to the end of the treatment period (Day45) |
Average total daily insulin (TDI) | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Average TDI/kg | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Change in weight | measures change in weight | Comparing baseline metrics to the end of the treatment period (Day45) |
Patient reported outcomes | Participant responses to various questionnaires related to the investigational device as well as managing diabetes | Comparing baseline metrics to the end of the treatment period (Day45) |
4-hour post prandial glycemic metrics | Glucose metric from study continuous glucose monitoring system | Comparing baseline metrics to the end of the treatment period (Day45) |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Age at time of consent 18-75 years (inclusive)
- Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening
- On current insulin regimen for at least 3 months prior to screening (i.e. basal-bolus, basal insulin only or premix)
- Basal-bolus (AID or non-AID pump & MDI) or premix users with A1C < 14% OR basal users on long or intermediate acting insulin only with A1C > 8.0% and < 14%
- Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic equivalents
- Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
- If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.
- Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
- Willing to wear the system, including Pods, continuously throughout the study
- Willing and able to sign the Informed Consent Form (ICF)
- Able to read and understand English
- If of childbearing potential, willing and able to have pregnancy testing
- Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.
- Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
- Any planned surgery during the study which could be considered major in the opinion of the Investigator
- History of more than 1 severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
- History of more than 1 diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
- Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
- Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c
- Use of hydroxyurea
- Plans to receive blood transfusion over the course of the study
- Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal).
- Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
- Participation in another clinical study using an investigational drug or device within 30-days or intends to participate in any other study during this study period
- Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
- Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
Insulet CorporationNo contact data.
6 Study Locations in 1 Countries
Massachusetts
Joslin Diabetes, Boston, Massachusetts, 02215, United States
MassResearch LLC., Waltham, Massachusetts, 02453, United States
Michigan
Henry Ford Health, Detroit, Michigan, 48202, United States
North Carolina
Mountain Area Health Educational Center ( MAHEC), Asheville, North Carolina, 28803, United States
Texas
Texas Diabetes and Endocrinology (TDE), Austin, Texas, 78731, United States
Disease & Glandular Disease Clinic, San Antonio, Texas, 78229, United States